Skip to main content
RT

Retina Technologies

Retina Technologies develops the OcuVue™ modular vision screening system, which utilizes machine learning algorithms and miniaturized retinal imaging to provide accurate and rapid vision exams. This technology addresses the lack of accessible vision care, particularly in areas without eye care professionals, by enabling early detection of preventable vision loss and abnormalities.

East New York, United StatesFounded 20186300+ followers
Updated 4 months ago

Funding

$320K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

A significant portion of the population lacks access to regular vision screenings, particularly in regions with limited eye care professionals. This lack of access hinders early detection of preventable vision loss and abnormalities, leading to delayed treatment and potential vision impairment.

Solution

Retina Technologies offers OcuVue™, a modular vision screening system designed to provide accessible and rapid vision exams. The system utilizes miniaturized retinal cameras and machine learning algorithms to enable comprehensive vision assessments in various settings. OcuVue™ aims to address the challenges of traditional vision screening by offering a portable, user-friendly solution that facilitates early detection and timely referrals for specialized care. The device is designed to be used by any physician or vision specialist to provide a quantitative vision exam with reliable results.

Target Audience

The primary target audience includes physicians, vision specialists, and healthcare providers seeking accessible and efficient vision screening tools for early detection of vision loss and abnormalities.

Features

  • Head-mounted modular design for comprehensive vision testing anywhere, anytime
  • Miniaturized retinal cameras for rapid retinal photography
  • Proprietary, multi-dimensional analyses and machine learning algorithms for early detection of vision loss and abnormalities
  • Clinical validation against gold standards to ensure clinically proven test results
This profile is AI-generated and may contain inaccuracies.